AI assistant
Marksans Pharma Ltd. — M&A Activity 2026
Jul 8, 2026
62142_rns_2026-07-08_bd7225f5-a713-4d79-a20b-575742676bbd.pdf
M&A Activity
Open in viewerOpens in your device viewer
^{}[] M
Marksans Pharma Ltd.
Date: 08 July 2026
BSE Limited
Corporate Relation Department
Phiroze Jeejeebhoi Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 524404
National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS
Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015– Acquisition of ABCnow GmbH.
Dear Sirs/Madam,
Kindly be informed that Marksans Pharma Limited has entered into a definitive agreement to acquire 100% of the share capital of ABCnow GmbH, a Germany based pharmaceutical company with front-end sales, marketing, and distribution capabilities across German healthcare market.
The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.
Enclosed herewith please find details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/ 4/2015 dated September 9, 2015 given in Annexure A to this letter.
For Marksans Pharma Limited
H
PANIGRAHI
Digitally signed
by H PANIGRAHI
Date: 2026.07.08
10:00:35 +05'30'
Harshavardhan Panigrahi
Company Secretary
Enclosed as above
^{}[] Marksans Pharma Ltd.
^{}[] 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000
^{}[] E-mail: [email protected]
^{}[] www.marksanspharma.com
^{}[] M
Marksans Pharma Ltd.
Annexure A
Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
| Sr. No. | Details of Events that need to be provided | Information of such events(s) |
|---|---|---|
| 1 | Name of the target entity, details in brief such as size, turnover etc. | ABCnow GmbH is a foreign company registered in Germany. It is a pharmaceutical wholesale and distribution company headquartered in Flensburg, Germany. It is primarily engaged in marketing & distribution of OTC products in Germany. It has a turnover of € 227,233.69 as on December 31, 2025. |
| 2 | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” | The transaction is between the Company and the shareholders of ABCnow GmbH, who are not related party to the Company. As such, the transaction will not fall within related party transaction(s) for the Company. Further, promoter/promoter group of the Company have no interest in ABCnow GmbH. |
| 3 | Industry to which the entity being acquired belongs | ABCnow GmbH is a pharmaceutical wholesale and distribution company headquartered in Flensburg, Germany. |
| 4 | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of ABCnow GmbH for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans’ presence in the European markets. |
| 5 | Brief details of any governmental or regulatory approvals required for the acquisition | No approval will be required for the acquisition. |
| 6 | Indicative time period for completion of the acquisition | The acquisition is expected to be completed by 31 July 2026. |
| 7 | Nature of consideration - whether cash consideration or share swap and details of the same | Cash consideration |
| 8 | Cost of acquisition or the price at which the shares are acquired | The Company will acquire entire shareholding of ABCnow GmbH for a total consideration of € 892,384. |
| 9 | Percentage of shareholding / control acquired and / or number of shares acquired | The Company will acquire 100% share capital of ABCnow GmbH. |
| 10 | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | ABCnow GmbH is a pharmaceutical wholesale and distribution company headquartered in Flensburg, Germany. It is primarily engaged in marketing & distribution of OTC products in Germany. ABCnow presents an attractive opportunity to gain access to German pharma markets and with its capable and well-trained team of professionals can support Marksans’ growth aspirations. With this acquisition, Marksans will create its own front end in Germany to market its products. It was incorporated in the year 2023 and it achieved revenue of € 510,215.60 in 2024 and € 227,233.69 in 2025. |
^{}[] Marksans Pharma Ltd. H PANIGRAHI Digitally signed by H PANIGRAHI Date:2026.07.08 10:01:51 +05'30'
^{}[] 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: [email protected] www.marksanspharma.com